{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:52:21Z","timestamp":1792043541368,"version":"4.4.0"},"reference-count":40,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2022,3,31]]},"DOI":"10.7883\/yoken.jjid.2021.367","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T22:10:29Z","timestamp":1627596629000},"page":"114-120","source":"Crossref","is-referenced-by-count":3,"title":["Risk\u2013Benefit Analysis of the 9-Valent HPV Vaccination for Adolescent Boys from an Individual Perspective"],"prefix":"10.7883","volume":"75","author":[{"given":"Taito","family":"Kitano","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, The Hospital for Sick Children, Canada"},{"name":"Department of Pediatrics, Nara Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Moreira ED Jr, Block SL, Ferris D, et al. Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138:e20154387.","DOI":"10.1542\/peds.2015-4387"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: Results of the Nagoya study. Papillomavirus Res. 2018;5:96-103.","DOI":"10.1016\/j.pvr.2018.02.002"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kitano T. The estimated burden of 15 vaccine-preventable diseases from 2008 to 2020 in Japan: A transition by the COVID-19 pandemic. J Infect Chemother. 2021;27:1482-1488.","DOI":"10.1016\/j.jiac.2021.06.021"},{"key":"4","unstructured":"4. European Centre for Disease Prevention and Control (ECDC). ECDC Scientific Advice: Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. Stockholm: ECDC; 2020."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Mizumachi K, Aoki H, Kitano T, et al. How to recover lost vaccine acceptance? A multi-center survey on HPV vaccine acceptance in Japan. J Infect Chemother. 2021;27:445-449.","DOI":"10.1016\/j.jiac.2020.10.012"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kitano T. Stopping the HPV vaccine crisis in Japan: Quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making. J Infect Chemother. 2020;26:225-230.","DOI":"10.1016\/j.jiac.2019.09.005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. N\u00e4sman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287:134-152.","DOI":"10.1111\/joim.13010"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Prieto L, Sacrist\u00e1n JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80.","DOI":"10.1186\/1477-7525-1-80"},{"key":"9","unstructured":"9. Ministry of Health, Labour and Welfare. List of Statistical Surveys conducted by Ministry of Health, Labour and Welfare. Available at &lt;https:\/\/www.mhlw.go.jp\/toukei\/itiran\/eiyaku.html&gt;. Accessed May 6, 2021."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443-8450.","DOI":"10.1016\/j.vaccine.2011.07.096"},{"key":"11","unstructured":"11. National Cancer Center Japan. Cancer Registry and Statistics. Cancer Information Service, (National Cancer Registry, Ministry of Health, Labour and Welfare). Available at &lt;https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html&gt;. Accessed March 6, 2021."},{"key":"12","unstructured":"12. International Agency for Research on Cancer. Global Cancer Observatory. Available at &lt;https:\/\/gco.iarc.fr\/&gt;. Accessed May 4, 2021."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kawado M, Hashimoto S, Ohta A, et al. Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. BMC Infect Dis. 2020;20:77.","DOI":"10.1186\/s12879-020-4801-x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121:1386-1391.","DOI":"10.1001\/archotol.1995.01890120044008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Deng Z, Hasegawa M, Matayoshi S, et al. Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan. Eur Arch Otorhinolaryngol. 2011;268:1625-1631.","DOI":"10.1007\/s00405-011-1515-0"},{"key":"16","unstructured":"16. Japan Society for Head and Neck Cancer, Cancer Registry Committee. Report of Head and Neck Cancer Registry of Japan. Clinical Statistics of Registered Patients, 2016. Available at &lt;http:\/\/www.jshnc.umin.ne.jp\/pdf\/2016syourei_houkoku.pdf&gt;. Accessed May 4, 2021."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136:98-107.","DOI":"10.1002\/ijc.28963"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sakamoto J, Shigehara K, Nakashima K, et al. Etiological role of human papillomavirus infection in the development of penile cancer. Int J Infect Dis. 2019;78:148-154.","DOI":"10.1016\/j.ijid.2018.11.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sakuma S, Minagawa H, Mori R, et al. Human papillomavirus DNA in condylomata acuminata from Japanese males. Diagn Microbiol Infect Dis. 1988;10:23-29.","DOI":"10.1016\/0732-8893(88)90123-X"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kin Cho Goon P, Scholtz LU, Sudhoff H. Recurrent respiratory papillomatosis (RRP)-time for a reckoning? Laryngoscope Investig Otolaryngol. 2017;2:184-186.","DOI":"10.1002\/lio2.80"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711-723.","DOI":"10.1056\/NEJMoa1405044"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sullivan PW, Slejko JF, Sculpher MJ, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31:800-804.","DOI":"10.1177\/0272989X11401031"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14:244-251.","DOI":"10.3201\/eid1402.070499"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Marcellusi A, Capone A, Favato G, et al. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Clin Ther. 2015;37:156-167.e4.","DOI":"10.1016\/j.clinthera.2014.11.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Monta\u00f1o-Vel\u00e1zquez BB, Nolasco-Renero J, Parada-Ba\u00f1uelos JE, et al. Quality of life of young patients with recurrent respiratory papillomatosis. J Laryngol Otol. 2017;131:425-428.","DOI":"10.1017\/S0022215117000354"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis. 2009;36:515-521.","DOI":"10.1097\/OLQ.0b013e3181a74c2c"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Loizou C, Laurell G, Arvidsson A, et al. Recurrent respiratory papillomatosis in northern Sweden: clinical characteristics and practical guidance. Acta Otolaryngol. 2015;135:1058-1064.","DOI":"10.3109\/00016489.2015.1048378"},{"key":"28","unstructured":"28. Ministry of Health, Labour and Welfare. Incidence of reported symptoms after HPV vaccination in Japan. Available at &lt;https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000186458.pdf&gt;. Accessed May 10, 2021. Japanese."},{"key":"29","unstructured":"29. Ministry of Health, Labour and Welfare. Active surveillance of HPV vaccine adverse reaction. Available at &lt;https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou28\/chousa\/dl\/160212_02.pdf&gt;. Accessed May 10, 2021. Japanese."},{"key":"30","unstructured":"30. Ministry of Health, Labour and Welfare. Health and Labour Sciences Research Grants. National epidemiological survey on treatment situation of adolescent variety symptoms (pain and motor disabilities); Epidemiological study about the evaluation for the efficacy and safety of HPV vaccine. Available at &lt;https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000147016.pdf&gt;. Accessed May 10, 2021. Japanese."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kitano T, Onaka M, Ishihara M, et al. Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital. Clin Exp Vaccine Res. 2017;6:120-127.","DOI":"10.7774\/cevr.2017.6.2.120"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Narayanan UG, Fehlings D, Weir S, et al. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol. 2006;48:804-812.","DOI":"10.1111\/j.1469-8749.2006.tb01227.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Bayle-Iniguez X, Audouin-Pajot C, Sales de Gauzy J, et al. Complex regional pain syndrome type I in children. Clinical description and quality of life. Orthop Traumatol Surg Res. 2015;101:745-748.","DOI":"10.1016\/j.otsr.2015.06.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Cody P, Tobe K, Abe M, et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21:11.","DOI":"10.1186\/s12879-020-05632-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401-411.","DOI":"10.1056\/NEJMoa0909537"},{"key":"36","unstructured":"36. Brisson M, B\u00e9nard \u00c9, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1:e8-e17."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Burger EA, Kim JJ, Sy S, et al. Age of acquiring causal human papillomavirus (HPV) infections: Leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis. 2017;65:893-899.","DOI":"10.1093\/cid\/cix475"},{"key":"38","unstructured":"38. Ministry of Health, Labour and Welfare and National Institute of Infectious Diseases. [Category V Infectious Diseases, Sexually Transmitted Diseases, Condyloma acuminatum]. Infect Dis Wkly Rep Jpn. 2019. Available at &lt;https:\/\/www.niid.go.jp\/niid\/ja\/ydata\/10071-report-jb2019.html&gt;. Accessed May 10, 2021. Japanese."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018;23:1700737.","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Arie S. HPV: WHO calls for countries to suspend vaccination of boys. BMJ. 2019;367:16765.","DOI":"10.1136\/bmj.l6765"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/2\/75_JJID.2021.367\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:15:14Z","timestamp":1715231714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/75\/2\/75_JJID.2021.367\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2021.367","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"JJID.2021.367"}}